Epigenetics Market To Register A Moderate CAGR During Foreca...| MENAFN.COM

Wednesday, 01 February 2023 12:20 GMT

Epigenetics Market To Register A Moderate CAGR During Forecast Period 2022 2032 : Fact.MR X Herald


(MENAFN- Ameliorate Digital Consultancy)

As per the latest report published by Fact.MR, a market research and competitive intelligence provider, the global epigenetics market is slated to be worth US$ 992.8 Mn in 2022 and have a CAGR of 10.9% from 2022 to 2032. Fact.MR has a hawk's eye with regards to epigenetics market. It states that demand for products like mass spectrometers, DNA-modifying enzymes, sonicators, biculfite conversion kits, and likewise is bound to take the epigenetics market to US$ 2.79 Bn by the year 2032.

Download Free Sample Copy of this Report: 

Key Segments Covered in Epigenetics Industry Research

  • Epigenetics Market by Product :
    • Epigenetic Kits
    • Epigenetic Reagents
    • Epigenetic Enzymes
    • Bioinformatics Tools
    • Epigenetics Instruments and Consumables
    • Others
  • Epigenetics Market by Technology :
    • Epigenetics DNA Methylation
    • Histone Methylation
    • Histone Acetylation
    • MicroRNA modification
    • Chromatic structures
    • Others
  • Epigenetics Market by Application :
    • Immunology
    • Oncology
    • Cardiovascular Diseases
    • Metabolic Diseases
    • Non-Oncology
    • Others
  • Epigenetics Market by Region :
    • North America
    • Latin America
    • Europe
    • APAC
    • MEA

Get Customization on this Report for Specific Research Solutions –

Key Takeaways from Market Study

  • Europe holds 27.1% of the market share.
  • Epigenetic biomarkers as well as diagnostics are bound to take the epigenetics market by storm in the next 10 years.

Competitive Landscape

Epigenetic service providers are concentrating on mergers, collaborations, acquisitions, and partnerships to broaden their business reach and support their R&D efforts to hasten the introduction of cutting-edge epigenetic technology.

  • Grail, a business specialising in the early detection of various cancers, was purchased by Illumina Inc., a significant American biotechnology company, in August 2021. Grail was taking patients for a trial to expand its dataset focusing on the genome associated with cancer-causing epigenetic factors as it prepared its application for an FDA approval of its Galleri test.

Fact.MR, a market research and competitive intelligence provider, has profiled key companies such as Thermo Fisher Scientific, PerkinElmer, Illumina, New England Biolabs, Merck Millipore, Abcam, and Agilent, among others, in this latest epigenetics market survey.

For in-depth competitive analysis, Buy Now – 

Market Developments

The key participants are targeting mergers and acquisitions to make a mark in the epigenetics market. Start-ups are at the forefront in this regard.

  • The US-based Element Biosciences, Inc. is emphasizing on development of several innovation-based genetic analysis tools to serve the purpose of research and diagnostics. Along these lines, it did announce partnering with Dovetail Genomics (firm specializing in redefining genomic biology). This partnership is slated to demonstrate and explore ligation-based NGS (next-generation sequencing) library prep solutions of Dovetail on Element's novel AVITI System.
  • Grain, in August 2021, got acquired by Illumina Inc. with the objective of expanding the dataset emphasizing on genome related to cancer-causing epigenetic factors.

For More Insight- 

About Us:

Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we'll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email:
Visit Our Website:

MENAFN10112022004660010643ID1105163098


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.